Lixte Biotechnology Announces a Clinical Trial Agreement with Moffitt Cancer Center to Initiate Phase 1b/2 Trial Evaluating the Safety and Efficacy of LB-100 in Treatment of Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome
1911 Gold Closes C$13.2 Million "Bought Deal" Life Offering Including Increased Investment by Eric Sprott
